NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-361-2001-0-PCT-02 A Method and Apparatus to Improve an MRI Image PCT PCT PCT/US2002/033571 Expired
CC E-207-2001-1-US-02 BIOPSY APPARATUS WITH RADIO FREQUENCY CAUTERIZATION AND METHODS FOR ITS USE US ORD 10/274,074 Abandoned
NIMH E-242-2003-0-US-01 Direct Use Of Tissue To Isolate Anti-HDS Modified Phage/ US 60/418,722 Abandoned
NCI E-130-2001-0-IN-06 Broadly Cross-Reactive Neutralizing Antibodies Against Human Immunodeficiency Virus selected By ENV-CD4-CO-Receptor Complexes IN National Stage 1073/CHEN/2004 Abandoned
NCI E-130-2001-0-AU-02 Broadly Cross-Reactive Neutralizing Antibodies Against Human Immunodeficiency Virus selected By ENV-CD4-CO-Receptor Complexes AU National Stage 2002337885 Abandoned
NCI E-130-2001-0-PCT-01 Broadly Cross-Reactive Neutralizing Antibodies Against Human Immunodeficiency Virus selected By ENV-CD4-CO-Receptor Complexes PCT PCT PCT/US02/33165 Abandoned
NCI E-096-2003-0-US-01 Use Of DDR1 And Agents That Affect The DDR1/Collagen Pathway US 60/419,179 Abandoned
NCI E-123-2003-0-US-01 Methods Of Treating Melanoma Using Cosalane US 60/419,058 Abandoned
NCI E-046-1991-5-US-03 METHOD OF PREVENTING TUMOR METASTASIS (AS FILED) US CON 10/270,564 Abandoned
NCI E-130-2001-0-CA-04 Broadly Cross-Reactive Neutralizing Antibodies Against Human Immunodeficiency Virus Selected By ENV-CD4-CO-Receptor Complexes CA National Stage 2463931 Abandoned
NCI E-297-2002-0-CA-03 Methods of Preparing Lymphocytes That Express Interleukin-2 and Their Use in the Treatment of Cancer CA National Stage 2501087 Abandoned
NCI E-297-2002-0-AU-04 Methods of Preparing Lymphocytes that Express Interleukin-2 and their Use in the Treatment of Cancer AU National Stage 2002353822 Abandoned
NCI E-297-2002-0-PCT-01 Methods of Preparing Lymphocytes that Express Interleukins-2 and Their Use in the Treatment of Cancer PCT PCT PCT/US2002/033243 Expired
NIA E-146-1993-0-US-10 METHOD OF TREATING ATHEROSCLEROSIS OR RESTENOSIS USING MICROTUBULE STABILIZING AGENT US CON 10/272,496 Abandoned
NCI E-297-2002-0-EP-05 Methods of Preparing Lymphocytes that Express Interleukins-2 and Their Use in the Treatment of Cancer EP National Stage 02789213.2 Abandoned
NHLBI E-259-2002-0-US-01 Identification and Purification of Pulmonary Hypertensive Substances From Group B Streptococcus US 60/419,035 Abandoned
NIMH E-098-2001-1-US-01 Methods of Manipulating Nucleic Acids US CIP 10/269,515 Abandoned
NIDCR E-308-2003-1-US-01 Ligands of Eukarytic Translation Initiation Factor 5A (eIF-5A) and Their Use US 60/417,738 Abandoned
NCI E-121-2002-0-US-01 Identification of Anti-HIV Compounds Inhibiting Virus Assembly and Binding of Nucleocapsid Protein to Nucleic Acid US 60/416,854 Abandoned
NCI E-171-2000-0-JP-03 Highly Cross-Linked, Extremely Hydrophobic Nitric Oxide-Releaseing Polymers And Methods For Their Manufacture And Use JP ORD 2002-292578 Expired
NCI E-158-2001-0-PCT-01 Tandem Repeat Markers PCT PCT PCT/US2002/031634 Expired
NIDA E-057-2000-0-US-03 TREATMENT OF NEUROPSYCHIATRIC DISEASE WITH PROTEASE AND NEURAMINIDASE INHIBITORS US National Stage 10/182,162 Abandoned
NIMH E-247-2002-0-US-01 Anthrax Lethal Factor Represses the Glucocorticoid Receptor and Other Nuclear Receptors: Possible Role in Toxicity of Anthrax, Related Bacterial Products and Related Vaccines US 60/416,222 Abandoned
NCI E-293-2002-0-US-01 Vasoregulating Compounds and Methods of Their Use US 60/416,291 Abandoned
NIA E-138-2000-0-US-03 Tumor Markers in Ovarian Cancer US National Stage 10/257,021 7279294 Abandoned PDF
NIMH E-038-2007-3-PCT-02 Nucleic Acid Molecules, Polypeptides And Uses Therefor, Including Diagnosis And Treatment Of Alzheimer's Disease PCT PCT PCT/US02/31642 Expired
NIMH E-038-2007-4-US-01 Nucleic Acid Molecules, Polypeptides And Uses Therefor, Including Diagnosis And Treatment Of Alzheimer's Disease US CIP 10/264,309 Abandoned
NIMH E-038-2007-3-EP-03 Diagnosis and treatment of Alzheimer's disease EP ORD 02256893.5 Abandoned
NCI E-110-2002-0-US-01 Prediction Method for T Cell Epitopes Based on Quantitative Properties of MHC Binding Peptides US 60/416,034 Abandoned
NCI E-167-2007-0-RU-01 Antigenic Peptides RU ORD 20022126396 Abandoned
NCI E-148-1998-1-US-03 Molecular Clones With Mutated HIV GAG/POL,SIV GAG And SIV ENV Genes US CON 10/263,020 8076100 Expired PDF
NCI E-171-2000-0-EP-02 Highly Cross-Linked, Extremely Hydrophobic Nitric Oxide-Releaseing Polymers And Methods For Their Manufacture And Use EP National Stage 02256854.7 Expired
NINDS E-001-2003-0-US-01 A Nucleolar Mechanism Controlling Cell Proliferation In Stem Cells And Cancer Cells US 60/415,867 Abandoned
NCI E-262-1999-1-US-02 HGF-SF Monoclonal Antibody Combinations US National Stage 10/129,596 7459536 Expired PDF
NICHD E-069-2000-2-US-02 METHODS OF MAKING AND USING 7alpha, 11beta-DIMETHYL-17beta HYDROXYESTER-4-EN-3-ONE 17 Undecanoate US ORD 10/260,854 Abandoned
CC E-077-2002-0-US-01 Computer Aided Classification of Anomalies in Anatomical Structures US 60/415,308 Abandoned
NCI E-075-2001-0-PCT-01 Methods and Compositions for Production and Purification of Recombinant Staphylococcal Enterotoxin B (rSEB) PCT PCT PCT/US2002/031114 Expired
NIAID E-092-2003-0-PCT-02 Paramyxoviruses As Gene Transfer Vectors To Lung Cells PCT PCT PCT/US02/30813 Expired
NIAID E-092-2003-0-EP-04 Paramyxoviruses As Gene Transfer Vectors To Lung Cells EP National Stage 02763762.8 Abandoned
NINDS E-181-2002-0-US-01 Methods and Devices for Intramuscular Stimulation of Upper Airway and Swallowing Muscle Groups US 60/413,773 Abandoned
NCI E-129-2001-0-CA-06 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. CA National Stage 2461351 Expired
NCI E-129-2001-0-ES-09 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. ES EP 02761818.0 Expired
NCI E-129-2001-0-IT-12 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. IT EP 02761818.0 Expired
NCI E-129-2001-0-GB-11 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. GB EP 02761818.0 Expired
NCI E-129-2001-0-FR-10 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. FR EP 02761818.0 Expired
NCI E-129-2001-0-DE-08 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. DE EP 02761818.0 Expired
NCI E-129-2001-0-EP-04 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. EP National Stage 02761818.0 Expired
NCI E-129-2001-0-AU-05 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. AU National Stage 2002327053 Expired
NCI E-347-2003-3-US-02 Composite Antibodies of Humanized Human Subgroup IV Light Chain Capable of Binding to Tag-72 US DIV 10/255,478 7179899 Expired PDF
NCI E-129-2001-0-PCT-02 Mutated Anti-CD22 Antibodies with Increased Affinity To CD22 Expressing Leukemia Cells. PCT PCT PCT/US2002/030316 Expired